Cirrus Therapeutics is focused on ocular immunology and is based in Cambridge, Massachusetts. Its lead program is a preclinical adeno-associated virus (AAV) ocular gene therapy designed to restore IRAK-M, an immune regulator expressed in retinal cells. The company is targeting dry age-related macular degeneration with the goal of reversing disease and preventing progression to geographic atrophy. Cirrus has raised a seed round now totaling $14.7 million, initially announced at $11 million. Investors in the round include ClavystBio (lead), Polaris Partners, SEEDS (SG Growth Capital) and the Intellectual Property Company of Cedars-Sinai. The company is using the seed-stage capital to advance its preclinical program toward further development.

Total raised

$26M

Funding rounds

2

Latest round

Seed

Latest activity

Aug 2026